137 related articles for article (PubMed ID: 1989642)
1. Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells.
Workman P; Donaldson J; Lohmeyer M
Biochem Pharmacol; 1991 Jan; 41(2):319-22. PubMed ID: 1989642
[No Abstract] [Full Text] [Related]
2. Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells.
Dive C; Watson JV; Workman P
Cancer Res; 1991 Feb; 51(3):799-806. PubMed ID: 1988120
[TBL] [Abstract][Full Text] [Related]
3. Lack of enantio-selectivity in the in vitro antitumour cytotoxicity and membrane-damaging activity of ether lipid SRI 62-834: further evidence for a non-receptor-mediated mechanism of action.
Lohmeyer M; Workman P
Biochem Pharmacol; 1992 Aug; 44(4):819-23. PubMed ID: 1510728
[TBL] [Abstract][Full Text] [Related]
4. [Platelet-activating factor (PAF) antagonists].
Terasawa M
Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):379-87. PubMed ID: 1850862
[No Abstract] [Full Text] [Related]
5. Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells.
Cellai C; Laurenzana A; Vannucchi AM; Della Malva N; Bianchi L; Paoletti F
FASEB J; 2002 May; 16(7):733-5. PubMed ID: 11923217
[TBL] [Abstract][Full Text] [Related]
6. Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids.
Lohmeyer M; Workman P
Br J Cancer; 1995 Aug; 72(2):277-86. PubMed ID: 7640206
[TBL] [Abstract][Full Text] [Related]
7. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
[TBL] [Abstract][Full Text] [Related]
8. An antagonist to platelet activating factor counteracts the tumoricidal action of alkyl lysophospholipids.
Bazill GW; Dexter TM
Biochem Pharmacol; 1989 Jan; 38(2):374-7. PubMed ID: 2536543
[No Abstract] [Full Text] [Related]
9. Inhibition of neutrophil respiratory burst and degranulation responses to platelet-activating factor by antagonists WEB 2086, CV 6209 and CV 3988.
Bates EJ; Harvey DP; Ferrante A
Int Arch Allergy Immunol; 1992; 97(1):50-6. PubMed ID: 1582698
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary vascular reactivity: effect of PAF and PAF antagonists.
Chen CR; Voelkel NF; Chang SW
J Appl Physiol (1985); 1992 Nov; 73(5):1762-9. PubMed ID: 1474049
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of neutrophil and eosinophil chemotactic responses to PAF by the PAF-antagonists WEB-2086, L-652,731, and SRI-63441.
Håkansson L; Venge P
J Leukoc Biol; 1990 May; 47(5):449-56. PubMed ID: 2335754
[TBL] [Abstract][Full Text] [Related]
12. Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells.
Bazill GW; Dexter TM
Cancer Res; 1990 Dec; 50(23):7505-12. PubMed ID: 2253199
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of synthetic alkylphospholipids with or without PAF activity.
Kudo I; Nojima S; Chang HW; Yanoshita R; Hayashi H; Kondo E; Nomura H; Inoue K
Lipids; 1987 Nov; 22(11):862-7. PubMed ID: 3444379
[TBL] [Abstract][Full Text] [Related]
15. The effect of ether lipid 1-O-octadecyl-2-O-methoxy-rac-glycero-3-phosphocholine and its analogues platelet activating factor and carbamyl-platelet activating factor on the biosynthesis of interleukin-6 in human thymic epithelial cells cultivated in vitro.
Cardile V; Mascarucci P; De Simoni MG; Jiang X; Bindoni M
Cytokine; 1996 Sep; 8(9):698-701. PubMed ID: 8932980
[TBL] [Abstract][Full Text] [Related]
16. A flow cytometric assay reveals an enhancement of phagocytosis by platelet activating factor in murine peritoneal macrophages.
Ichinose M; Hara N; Sawada M; Maeno T
Cell Immunol; 1994 Jul; 156(2):508-18. PubMed ID: 8025959
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological analysis of neutrophil chemotactic factor production by leucocytes and roles of PAF in allergic inflammation in rats.
Watanabe M; Arakida Y; Tanabe J; Sugidachi A; Hirasawa N; Mue S; Ohuchi K
Br J Pharmacol; 1994 Jan; 111(1):123-30. PubMed ID: 8012688
[TBL] [Abstract][Full Text] [Related]
18. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist.
Yue TL; Gleason MM; Gu JL; Lysko PG; Hallenbeck J; Feuerstein G
J Pharmacol Exp Ther; 1991 Apr; 257(1):374-81. PubMed ID: 1850473
[TBL] [Abstract][Full Text] [Related]
19. Dissociation of the effects of the antitumour ether lipid ET-18-OCH3 on cytosolic calcium and on apoptosis.
Alonso MT; Gajate C; Mollinedo F; Modolell M; Alvarez J; García-Sancho J
Br J Pharmacol; 1997 Aug; 121(7):1364-8. PubMed ID: 9257915
[TBL] [Abstract][Full Text] [Related]
20. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
